Oculis up after eye drug meets main goal in late-stage study

Oculis Holding AG

22/05/2023 16:12

** U.S.-listed shares of Swiss-based Oculis Holding  OCS.O 
 7DQ.F  rise 5.8% to $12.8
    ** Co's experimental drug to treat a type of eye disorder
met its main goal in a late-stage study 
    ** The drug, ‍OCS-01​, is being developed to treat diabetic
macular edema which is a leading cause of blindness in patients
with diabetes
    ** Patients treated with the drug showed strong visual gain
compared to a vehicle, which is similar to a placebo - OCS
    ** Co adds ‍OCS-01 was well-tolerated in the study and plans
to begin a second part of its late-stage study later this year
    ** Including session moves, stock up 26.24% so far in the
year

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))